A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott

Criteria

INCLUSION CRITERIA:

• Current diagnosis of probable Alzheimer's disease.

• ADAS-cog score of at least 12 and MMSE score of 10 to 26.

• Non-smoker

• Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person.

• Fluent in English.

EXCLUSION CRITERIA:

• Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks.

• Has clinically significant or uncontrolled medical condition other than Alzheimer's disease.

• Nursing home resident.